I make a donation
I make a donation
En cours
objectif
Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.
date de réalisation
2020
nombre de patients
554
nombre de centres participants
12 french sites
type de financement
Public (APHP)
Référence
NCT04329195
ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection : the Randomized ACORES-2 Study
Since December 2019, a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused an international outbreak of respiratory illness described as COVID-19.
Individuals with a history of cardiovascular disease develop a more severe illness and have higher rates of death.
Because of the potential interaction between RAS blockers and SARS-CoV-2 mechanism of infection, there are ongoing scientific discussions on whether they should be stopped or continued in patients with COVID-19.
It is crucial to determine whether RAS blockers should be discontinued or not in patients with COVID-19.
En cours
En cours
En cours
